Protalix BioTherapeutics, Inc. (PLX) Friday said its product ELELYSO has been approved in Canada for the treatment of Gaucher Disease in both adult and pediatric patients.
Pfizer Inc. (PFE), the commercial partner of Protalix will market ELELYSO in Canada.
Einat Brill Almon, Protalix's Senior Vice President of Product Development, commented: "With the Canadian approval of ELELYSO, the drug is now approved for patients in more than ten countries across the globe" ELELYSO was approved in the U.S. in 2012.
For comments and feedback: editorial@rttnews.com